Company: ANTX
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0000950170-25-070358
Chunk: 0

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Item 1
Chunk 0
---
AN2 THERAPEUTICS, INC.

CONDENSED BALANCE SHEETS

(in thousands, except share and per share amounts)

(unaudited)

     March 31,

     December 31,

     2025

     2024

     Assets

     Current assets:

     Cash and cash equivalents
      
     $
     19,985

     $
     21,351

     Short-term investments

     47,075

     62,267

     Prepaid expenses and other current assets

     2,499

     2,644

     Total current assets

     69,559

     86,262

     Long-term investments

     11,480

     5,021

     Other assets, long-term

     304

     804

     Total assets
      
     $
     81,343

     $
     92,087

     Liabilities and stockholders’ equity

     Current liabilities:

     Accounts payable
      
     $
     3,073

     $
     3,317

     Accrued compensation

     529

     1,676

     Accrued liabilities

     4,043

     4,454

     Other current liabilities

     369

     791

     Total liabilities

     8,014

     10,238

     Commitments and contingencies (Note 7)

     Stockholders’ equity:

     Preferred stock, $0.00001 par value; 10,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024

     —

     —

     Common stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2025 and December 31, 2024; 30,141,517 and 29,919,634 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively

     —

     —

     Additional paid-in capital

     289,706

     287,594

     Accumulated other comprehensive gain

     48

     31

     Accumulated deficit

     (216,425
     )

     (205,776
     )

     Total stockholders